Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Aiming To Challenge Pfizer In Cardiomyopathy

 
• By Andrew McConaghie
  
Alnylam building
Alnylam is depending on the trial to expand into treating ATTR cardiomyopathy patients. • Source: Alamy

More from Business

More from Scrip